| Line 55: | Line 55: | ||
===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | ||
*This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | *This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | ||
===2021: [https://onlinelibrary.wiley.com/doi/10.1111/add.15628?fbclid=IwAR1Dliz9fOj83wYQ3muEXwsV_ZdVvi0d-ggBaJStLJqVl0Va3dpHfwt0Twg E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: Randomised controlled trial]=== | |||
*Participants previously unable to stop smoking with conventional treatments. | |||
*Validated smoking reduction (including cessation) was achieved by 26.5% vs 6.0% of participants in the EC and NRT study arms, respectively. Sustained validated abstinence rates at 6 months were 19.1% vs 3.0%. | |||
*[https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.15628 PDF Version] | |||
*Citation: Myers Smith, K., Phillips-Waller, A., Pesola, F., McRobbie, H., Przulj, D., Orzol, M., and Hajek, P. (2021) E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: Randomised controlled trial. Addiction, doi.org/10.1111/add.15628 | |||
*Acknowledgements: The study was funded by a Tobacco Advisory Group project grant, Cancer Research UK (C6815/A20503). | |||
<br> | <br> | ||
edits